Ligand Pharmaceuticals Inc (LGND) revenue by segment
LGNDNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as LGNDZ, LGNXZ, LGNYZ, LGNZZ
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 6/30437% above fair value
$286.94−11.77 (-3.94%)
Close on Nov 19, 2026Market cap $5.74BP/E 125.3Yield –
Doanh thu theo bộ phận của Ligand Pharmaceuticals Inc
Theo bộ phận kinh doanh
Theo sản phẩm hoặc dịch vụ
| Doanh thu | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % doanh thu | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalties | $161.00M | $108.77M | $84.96M | $72.91M | $48.93M | $33.80M | $46.98M | $128.56M | $88.69M | $59.42M | 60.1% | +48.0% |
| Revenue from intangible royalty assets | $132.53M | $95.33M | $83.91M | $72.53M | – | – | – | – | – | – | 49.4% | +39.0% |
| Contract revenue | $66.87M | $27.48M | $17.98M | $18.84M | $28.37M | $19.81M | $41.82M | $93.77M | – | – | 24.9% | +143.4% |
| Contract revenue and income | $66.87M | $27.48M | $17.98M | $18.84M | – | – | – | – | – | – | 24.9% | +143.4% |
| Income from Pelthos Transaction | $53.07M | $0 | $0 | – | – | – | – | – | – | – | 19.8% | – |
| Captisol | $40.21M | $30.88M | $28.37M | $104.50M | $164.25M | $109.96M | $31.49M | $29.12M | $22.07M | $22.50M | 15.0% | +30.2% |
| Kyprolis | $35.53M | $38.38M | $35.64M | $30.12M | $27.47M | $25.16M | $25.05M | $21.69M | – | – | 13.3% | -7.4% |
| Filspari | $31.97M | $12.18M | $2.66M | $0 | – | – | – | – | – | – | 11.9% | +162.5% |
| Income from financial royalty assets | $28.47M | $13.44M | $1.05M | $385.00K | – | – | – | – | – | – | 10.6% | +111.7% |
| Qarziba | $23.74M | $11.12M | $0 | – | – | – | – | – | – | – | 8.9% | +113.5% |
| Rylaze | $13.35M | $13.74M | $13.52M | $8.80M | $2.42M | $0 | – | – | – | – | 5.0% | -2.9% |
| Capvaxive | $10.06M | $626.00K | $0 | – | – | – | – | – | – | – | 3.8% | +1506.9% |
| Ohtuvayre | $9.76M | $833.00K | $0 | – | – | – | – | – | – | – | 3.6% | +1071.7% |
| Teriparatide injection | $8.15M | $8.22M | $11.06M | $15.79M | $5.26M | $0 | – | – | – | – | 3.0% | -0.9% |
| Vaxneuvance | $7.40M | $5.18M | $4.06M | $1.08M | – | – | – | – | – | – | 2.8% | +42.8% |
| Income | $6.99M | $1.94M | $0 | $0 | $634.00K | $119.00K | $6.20M | $78.20M | $13.67M | $10.57M | 2.6% | +259.5% |
| Evomela | $5.94M | $8.68M | $10.21M | $10.20M | $10.08M | $6.38M | $5.17M | $5.66M | – | – | 2.2% | -31.5% |
| Other | $4.73M | $2.32M | $1.05M | $6.55M | $3.70M | $2.26M | $2.57M | $1.95M | $5.59M | $387.00K | 1.8% | +103.4% |
| Captisol - COVID | – | $0 | $0 | $88.07M | $140.83M | $85.39M | – | – | – | – | – | – |
| Milestone | – | – | $16.80M | $9.15M | $17.58M | $5.22M | $17.17M | $6.58M | $11.09M | $16.09M | – | – |
| License fees, milestones and other revenues | – | – | – | – | – | – | $41.82M | $93.77M | $30.35M | $27.05M | – | – |
| Promacta | – | – | – | – | – | – | $14.19M | $99.26M | – | – | – | – |
Theo khu vực
Lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K, 10-Q của Ligand Pharmaceuticals (XBRL). Số quý 4 bằng cả năm tài chính trừ chín tháng đầu. Tên bộ phận giữ theo cách công ty tự đặt và có thể đổi khi công ty tái cấu trúc. Tab KPI hiện các bộ phận này cạnh chỉ số vận hành của Ligand Pharmaceuticals, kèm đầy đủ lịch sử, biểu đồ và liên kết tới từng hồ sơ.
See a number that looks wrong?